Business
HEMO-CAR-T cells Effective Against AML in vivo
HEMO-CAR-T cells Effective Against AML in vivo.
About this update from Hemogenyx Pharmaceuticals Plc
[{"type":"text","content":"\n \n \n RNS Number : 5325D\n Hemogenyx Pharmaceuticals PLC\n 20 February 2020\n \n \n \n \n Hemogenyx Pharmaceuticals plc\n \n \n (\"Hemogenyx\" or the \"Company\")\n \n \n \n \n \n Hemogenyx's CAR-T Cells are Effective Against AML in vivo\n \n \n \n \n \n \n \n \n Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments of blood diseases, is pleased to announce the following update on its activities.\n \n \n \n \n \n As previously announced, Hemogenyx's CDX product has the potential to treat Acute Myeloid Leukemia (AML) directly as well as to provide a benign conditioning regimen for blood stem cell replacement therapy. The Company has now carried out extensive work developing treatments for AML and has to date obtained highly encouraging results.\n \n \n \n \n \n In vivo testing of HEMO-CAR-T indicates anti-cancer activity in a mouse model\n \n \n \n \n \n As announced on 15 January 2020, Hemogenyx has successfully constructed Chimeric Antigen Receptor (CAR) programmed T cells (HEMO-CAR-T) for the potential treatment of AML. HEMO-CAR was constructed using Hemogenyx's proprietary humanised monoclonal antibody against a target on the surface of AML cells. The Company has now demonstrated in vivo that HEMO-CAR was able to programme human T cells (i.e. convert them into HEMO-CAR-T cells) to identify and destroy human AML derived cells. \n \n \n \n \n \n Additional engineering may improve safety and versatility of HEMO-CAR-T cells\n \n \n \n \n \n Following the successful completion of these tests, Hemogenyx is undertaking further engineering of HEMO-CAR to enhance the activity of the technology. The Company is introducing and testing a safety switch within the HEMO-CAR technology that is designed to control the level of activity of HEMO-CAR-T cells. The aim of this safety switch is to turn HEMO-CAR-T cells into a \"tunable and controllable drug\". The purpose of these efforts is to dramatically improve the safety and potential versatility of HEMO-CAR-T cells for the treatment of AML and/or conditioning of bone marrow transplants, as well as a number of additional potential indications.\n \n \n \n \n \n Vladislav Sandler, Chief Executive Officer, commented, \n \"\n We are encouraged by this new data which demonstrates ...